Cumberland Pharma (CPIX) Reports In-Line Q3 EPS of 6c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts CPIX Hot Sheet
Join SI Premium – FREE
Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) reported Q3 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $13.1 million versus the consensus estimate of $13.17 million.
Reaffirms guidance.
Reaffirms guidance.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
- Flotek raises 2026 revenue guidance to $360M-$370M range
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
